- Patent Title: Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
-
Application No.: US16330269Application Date: 2017-09-05
-
Publication No.: US11352438B2Publication Date: 2022-06-07
- Inventor: Koichiro Yoneyama , Christophe Schmitt
- Applicant: Chugai Seiyaku Kabushiki Kaisha , F. Hoffmann-La Roche AG
- Applicant Address: JP Tokyo; CH Basel
- Assignee: Chugai Seiyaku Kabushiki Kaisha,F. Hoffmann-La Roche AG
- Current Assignee: Chugai Seiyaku Kabushiki Kaisha,F. Hoffmann-La Roche AG
- Current Assignee Address: JP Tokyo; CH Basel
- Agency: Fish & Richardson P.C.
- International Application: PCT/JP2017/031933 WO 20170905
- International Announcement: WO2018/047813 WO 20180315
- Main IPC: C07K16/36
- IPC: C07K16/36 ; A61P7/04 ; A61K39/00

Abstract:
An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
Public/Granted literature
Information query